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Abstract
Introduction The contribution of CDH1 germline variants to gastric cancer burden among young adults is unknown in 
Brazil. We aimed to evaluate the frequency of CDH1 germline variants and the diet/lifestyle habits in early age onset gastric 
cancer (EOGC, ≤ 55 years old) patients.
Methodology From 2013 to 2015, a total of 88 unrelated and consecutive patients diagnosed with EOGC were enrolled. All 
CDH1 exons and intronic boundaries were sequenced, and large genomic rearrangements were screened by MLPA. CDH1 
transcription analysis was performed for variants that could potentially induce an effect on splicing. The diet and lifestyle 
habits of EOGC patients were compared to Brazilian population diet and lifestyle, obtained from governmental databases.
Results Of 88 patients, the mean age at EOGC diagnosis was 39 years and 55% fulfilled the criteria for hereditary diffuse 
gastric cancer. The majority of the tumors were diffuse (74%) and poorly differentiated (80%). In total, 4 novel missense 
variants of uncertain significance (VUS) were identified: c.313T>A, c.387G>T, c.1676G>A, and c.1806C>A. The MLPA 
results revealed no rearrangements and CDH1 transcription analysis for variants of interest were inconclusive. EOGC patients 
had a higher red (OR:2.6, 95%CI:1.4–4.9) and processed (OR:3.1, 95%CI:1.6–6.0) meat intake and higher fruit consumption 
(OR:0.4, 95%IC:0.3–0.7) compared to eating habits of the Brazilian population.
Conclusions No unequivocal pathogenic germline CDH1 variants were identified in Brazilian EOGC patients. Dietary habits 
may be associated with the EOGC development.
Keywords CDH1 · Diet · Hereditary diffuse gastric cancer · E-cadherin · Risk factors
Introduction
Gastric cancer is diagnosed in approximately 1 million peo-
ple globally, is responsible for 780.000 deaths each year, 
and is currently the third leading cause of cancer death 
worldwide [1]. Its incidence shows remarkable geographical Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1012 0-019-00945 -9) contains 
supplementary material, which is available to authorized users.
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variation. More than 70% of the cases occur in the develop-
ing countries, with the highest incidence rates observed in 
East Asia, Latin America, Central and Eastern Europe; and 
the lowest incidence in Africa and Northern America [2]. 
Brazil is considered a middle-/high-incidence country, with 
21.290 new cases expected in 2018 [3].
Although environmental and lifestyle factors—such as 
Helicobacter pylori infection, obesity, tobacco, alcoholic 
drinks, and foods preserved by salting and processed meat—
are major contributors to the etiology of this disease, famil-
ial aggregation is observed in approximately 10% of gastric 
cancer cases which are thought to be hereditary. Overall, 
only 1–3% arise as a result of inherited cancer predisposi-
tion syndromes [4]. Among the hereditary forms, the most 
important genetic mechanism is associated with germline 
mutations in the CDH1 gene (E-cadherin gene type 1, epi-
thelial cadherin, and OMIM #192,090), which encodes the 
protein called E-cadherin that is a transmembrane calcium-
dependent cell-adhesion molecule involved in cell-junction 
formation and the maintenance of epithelial integrity [5]. 
CDH1 germline pathogenic mutations cause hereditary dif-
fuse gastric cancer syndrome (HDGC) [6, 7].
Even though gastric cancer remains a major public health 
issue in South America, where countries in the region have 
some of the highest mortality rates worldwide, there is a lack 
of research focusing on risk factors influencing gastric can-
cer burden, specially those involving genetic inheritance. To 
date, only five germline variants of CDH1 were described in 
gastric cancer patients in South America: 4 in Brazil [8–10] 
(c.185G>T, c.1018A>G, c.1763_1764delTG, c.1023T>G), 
1 in Argentina [11] (c.1913G>A), and 1 in Colombia [6] 
(c.2245C>T). In general, germline CDH1 mutations were 
identified in subjects with a strong family history of diffuse 
gastric cancer or lobular breast cancer. However, a com-
bined analysis of 264 sporadic early age onset gastric cancer 
(EOGC) cases from low-incidence countries found that 2.3% 
of the subjects had a CDH1 germline pathogenic mutation 
[12], highlighting the importance to investigate hereditary 
cancer in this subpopulation.
Given the fact that inherited risk factors involved in the 
development of gastric cancer in Brazil are largely unex-
plored, we investigated the incidence and mutational spec-
trum of germline CDH1 variants as well as environmental 




Consecutive and unrelated patients diagnosed up to 
55 years old with gastric carcinoma, except those with 
neuroendocrine carcinoma, were invited to participate in 
the IRB approved study at Instituto do Câncer do Estado de 
São Paulo-Hospital das Clínicas da Faculdade de Medicina 
da Universidade de São Paulo (ICESP-HCFMUSP), Brazil. 
All patients who agreed to participate signed an informed 
consent, underwent genetic counseling, and donated blood 
for CDH1 complete sequencing. Personal and familial histo-
ries of cancer from EOCG patients were collected through a 
structured questionnaire. In addition, medical records were 
reviewed for all participants. Using the personal and family 
history data, probands were categorized based on whether 
they met International Gastric Cancer Linkage Consortium 
(IGCLC) criteria [13–16].
DNA extraction from blood
DNA was extracted from 8 mL of whole blood using the 
Biopur Kit Mini Spin Plus (Mobius Life Science, Pinhais, 
PR, Brazil) and Illustra Blood GenomicPrep Mini Spin Kit 
(GE Healthcare Bio-Sciences, Pittsburgh, PA, USA/28-
9042-64), following the instructions of the manufacturer.
Polymerase chain reaction (PCR) amplification, 
Sanger sequencing, and multiplex 
ligation‑dependent probe amplification of CDH1 
gene
Briefly, all exons and intron boundaries of CDH1 gene 
were amplified and sequenced in both forward and reverse 
directions. Primers and conditions are described in Sup-
plementary Table 1. Sequences obtained were visualized 
by Chromas (v2.33; Technelysium Pty, Ltd., Eden Prairie, 
MN, USA) and by Mutation Surveyor software (v3.20, Soft-
Genetics LLC, State College, PA, USA). All patients’ sam-
ples were submitted to Multiplex Ligation-Dependent Probe 
Amplification - MLPA technique  (SALSA®  MLPA® P083-
050R probemix; MRC-Holland, Amsterdam, The Nether-
lands), to investigate the presence of large rearrangements, 
as described in the Supplementary Materials.
CDH1 sequencing analysis and reporting criteria
All variants were named according to CDH1 sequence avail-
able at GenBank (NM_004360.4) using the nomenclature 
reported by the Human Genome Variation Society, HGVS 
(http://www.hgvs.org). The variants were searched for their 
classification in two publicly accessible databases: Leiden 
Open Variation Database (LOVD v3.0 build 13) and CLIN-
VAR [17], freeze January 2018.
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Allele frequencies of CDH1 variants
The difference of the prevalence of identified germline vari-
ants was evaluated in publicly available population datasets 
(ExAC—https ://doi.org/10.1038/natur e1905 7) and in 609 
Brazilian controls [18].
In silico analysis
Missense variants were analyzed in the following in silico 
prediction models: Polymorphism Phenotyping (PolyPhen; 
v2.2.2) [19], Sorting Intolerant From Tolerant (SIFT; v1.0.3) 
[20], Align-GV/GD [21], MutationTaster2 [22], and Protein 
Variation Effect Analyzer (Provean; v1.1) [23]. To check 
for intronic and exonic variants leading to potential splicing 
defects, the following prediction tools were used: Human 
Splicing Finder [24], Neural Network (NNS, v0.9) [25], 
MaxEntScan (MES) [26], and NetGene2 (NG2, v2.42) [27].
Variant classification
The variants were classified according to recommendations 
of the American College of Medical Genetics and Genomics 
in: pathogenic, likely pathogenic, benign, likely benign, and 
variant of uncertain significance (VUS) [28].
RNA extraction from paraffin‑embedded samples 
and characterization of the impact on splicing 
for CDH1 variants
Briefly, samples harboring CDH1 variants of interest were 
chosen for RNA extraction, further cloning, and sequencing, 
as shown in the Supplementary material.
Diet and lifestyle habits analysis
Diet and lifestyle information from EOCG patients was 
collected through a structured questionnaire. The exposure 
to smoking and alcohol intake was assessed through cat-
egories (never, former, and present use). The food intake 
of fruits, vegetables, leaves, red meat, processed meat, and 
salty food was assessed by intake frequency categories 
(less than once a week, once to twice a week, three-to-five 
times a week, and six-to-seven times a week). To esti-
mate the association of these factors and gastric cancer, 
information from Brazilian population diet and lifestyle 
databases was used as a control group. This information 
was retrieved from the following online public databases: 
Instituto Brasileiro de Geografia e Estatística (IBGE) [29], 
Sistema de Vigilância Alimentar e Nutricional (SISVAN) 
[30], and the Instituto Nacional de Ciência e Tecnologia 
para Políticas Públicas do Álcool e outras drogas (INPAD) 
[31]. These governmental data were obtained through pop-
ulation surveys from 2008 to 2015, and is representative of 
the Brazilian population. These surveys provided informa-
tion regarding smoking habits, alcohol consumption, and 
food-intake frequency through similar categories as used 
in our patients´ questionnaires. The associations between 
exposures to diet and lifestyle factors and gastric cancer 
were estimated using logistic regression and calculating 
the odds ratios (ORs) and 95% confidence intervals (CIs). 
For this, SPSS version 20 was used. P < 0.05 was consid-
ered as statistically significant.
Results
Population characteristics
From October 2013 to August 2015, 93 consecutive and 
unrelated patients diagnosed with gastric cancer ≤ 55 years 
were enrolled. However, two patients were not success-
ful in collecting blood and three patients were excluded, 
because the diagnosis changed after pathology review by 
a gastrointestinal pathologist at ICESP-HCFMUSP (two 
patients were diagnosed with neuroendocrine tumors, and 
in one patient, the malignancy was not confirmed in the 
histological study review).
The characteristics of the remaining 88 EOGC patients 
are shown in Table 1. The mean age at diagnosis was 
39 years. Patients were born in all regions of Brazil; most 
of them were originally from Southeast (50%) and North-
east (38.6%) regions (Supplementary Fig. 1). There was no 
difference between sexes. The majority of the tumors were 
diffuse (74%), poorly differentiated (80%), and located in 
the middle and distal-third of the stomach (67%). Most 
patients were diagnosed with locally advanced disease 
(27.3%) or metastatic (39.8%) disease. More than half 
underwent gastrectomy (58%) and about 28% initially 
treated with curative intent, had tumor recurrence. The H. 
pylori infection was confirmed in 6 out of 32 cases (infec-
tion status was unknown in 56 cases).
The cancer family history of the study participants is 
described in Table 1. In total, 23% and 8% of the probands 
had 1st or 2nd degree relatives diagnosed with gastric and/
or breast cancer, respectively. Nevertheless, the probands 
were not able to confirm neither inform the histologic sub-
type (e.g., diffuse or lobular) of those cancers diagnosed 
in their relatives. Because of that, none met the classical 
criteria postulated in 1999; however, the 2010 and 2015 
IGCLC criteria were fulfilled by 55% of the patients; 47% 
met the criteria due to the diagnosis of diffuse gastric can-
cer before 40 years of age.
923Frequency of CDH1 germline variants and contribution of dietary habits in early age onset gastric…
1 3
Complete CDH1 sequencing
Among these patients, 24 distinctive germline variants were 
identified (Table 2), including 5 (20.8%) missense, 6 (25%) 
synonymous, and 13 (54.2%) intronic variants. No large 
rearrangements were detected through MLPA.
Of the 24 variants, 9 were novel (c.49-61T>G, 
c.163+57G>A, c.163+59G>C, c.313T>A, c.387G>T, 
c.1676G>A, c.1806C>A, c.2164+16insA, and 
c.2439+56T>G) and 8 were classified as polymorphisms, 
because the population frequencies were greater than 
1% in the ExAC databank (c.48+6C>T, c.531+10G>C, 
c.1896C>T, c.1937-13T>C, c.2076T>C, c.2164+16insA, 
c.2253C>T, and c.2634C>T).
Excluding the eight variants classified as polymorphisms, 
32 patients presented CDH1 germline variants (regardless 
of their pathogenicity), corresponding to 36.4% of the cases 
(Supplementary Table 2).
In silico analyses of the missense variants
In total, five missense variants were identified; four of them 
were never previously reported: c.313T>A, c.387G>T, 
c.1676G>A, and c.1806C>A. In silico analyses of missense 
substitutions using five different prediction tools have shown 
conflicting results. All variants were considered benign by 
SIFT, PROVEAN, and PolyPhen-2 algorithms. On the other 
hand, Mutation Taster considered all the variants as poten-
tial disease causing. No variant has reached the maximum 
score of pathogenicity by the Align-GV/GD software, but 
the c.313T>A, c.387G>T e c.1676G>A achieved high 
scores (Table 3).
The missense mutation c.1849G>A has been previously 
reported. It was identified in four patients in our study: four 
women with diffuse gastric cancer diagnosed at 31, 35, 43, 
and 48 years. This variant was first described as a pathogenic 
somatic mutation in an endometrial [32] tumor and as a path-
ogenic germline mutation in a diffuse gastric cancer patient 
[33]. This variant is localized in the extracellular portion of 
E-cadherin, affecting a conserved sequence encoding one of 
the calcium-binding motifs. These calcium-binding motifs 
are functionally important, because the presence of calcium 
ions stabilizes the active conformation of the protein. Due 
to its position, it has been suggested that this mutation could 
lead to an unstable intercellular protein complex. In 2003, 
Suriano et al. identified this germline mutation in two Afri-
can–American female patients diagnosed with diffuse gas-
tric cancer at 43 years [34]. In this study, functional in vitro 
Table 1  Clinical–pathological characteristics of patients (n = 88)



























Poorly differentiated 70 (80%)
Moderately differentiated 4 (4%)













1st or 2nd degree relatives with gastric can-
cer < 50 years
7 (8%)
1st or 2nd degree relatives with gastric can-
cer > 50 years
13 (15%)
1st or 2nd degree relatives with breast cancer < 50 years 6 (7%)
1st or 2nd degree relatives with breast cancer > 50 years 1 (1%)
IGCLC criteria (1999) [13] 0 (0%)
IGCLC criteria (2010) [15] 48 (55%)
IGCLC criteria (2015) [16] 48 (55%)
Table 1  (continued)
Familial Gastric Cancer criteria [14] 59 (67%)
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analysis of the c.1849G>A mutation in a cell model resulted 
only in minor functional changes. A recent study identified 
the same germline variant in 6% (10/165) of African–Ameri-
can patients diagnosed with ductal or mixed carcinoma of 
the breast [35]. This frequency was similar to the allele 
frequency identified in the African population in EXAC 
(0.04622-481/10406, with 15 appearances in homozygous; 
http://exac.broad insti tute.org/varia nt/16-68856 041-G-A). In 
the Brazilian population controls, this mutation had allelic 
frequency of 0.006658. Therefore, due to the mild functional 
consequences observed in vitro assays and its high allele 
frequency, especially in the African-descendent population, 
this variant was classified as likely benign. This classifica-
tion is in concordance with the majority of the CLINVAR 
submission in which 14 of the 17 submission classified this 
variant as benign or likely benign (https ://www.ncbi.nlm.
nih.gov/clinv ar/varia tion/12232 /, accessed November 2018).
In silico prediction of splice‑affecting CDH1 
germline variants
The results of in silico tools for the prediction of splicing 
defect are described in Table 4. Five variants have been 
previously described as benign and in silico analyses really 
indicated their low pathogenicity: c.324A>G, c.345G>A, 
c.532-18C>T, c.833-16C>G, and c.2439+10C>T. Only one 
novel variant showed potential to affect the splicing process 
by three prediction tools: c.387G>T. This missense variant 
is located in the last nucleotide of the exon 3, leading to an 
amino acid substitution (glutamine-to-histidine). This vari-
ant may cause the alteration of the donor site and has the 
potential to affect splicing.
CDH1 germline variants of unknown significance 
and patients’ characteristics
Based on allele frequency, literature/databases searches, 
and in silico analysis, four variants were classified as VUS 
according to the recommendations of the American College 
of Medical Genetics and Genomics [22] (Table 5). These 
variants were identified in patients diagnosed with diffuse 
gastric adenocarcinoma; however, E-cadherin immuno-
expression was present in these tumor samples and these 
patients did not report a gastric cancer family history. These 
variants had never been described previously. It is notewor-
thy that VUS carriers were also exposed to environmental 
risk factors such as H. pylori infection, alcoholism, obesity, 
smoking, and red/processed meat consumption.
Evaluation of CDH1 mRNA from tumor samples
Nine FFPE tumor samples, presenting seven different vari-
ants, were further studied to evaluate mRNA splicing effects.
After mRNA extraction and cDNA synthesis, electropho-
resis in agarose gel revealed  no PCR product for six sam-
ples, probably due to mRNA degradation in the FFPE frag-
ment (n=5) or insufficient material (n = 1).  However, PCR 
products were detected for three tumor samples (Fig. 1): 
an amplicon of 178 bp, representing exons 3–4, on sam-
ple GH68 and an amplicon of 271 bp, representing exons 
15–16, on sample GH80. There was an unexpected amplicon 
of 238 bp on sample GH12. These products were cloned for 
cDNA sequencing
PCR products were also submitted to electrophoresis in 
polyacrylamide gel: for sample GH68, besides the fragment 
Table 3  In silico analysis, previously described functional analysis and databases entries of CDH1 germline missense variants
LOVD Leiden open variation database, NA not available, PolyPhen-2 v2 polymorphism phenotyping, PROVEAN protein variation effect ana-
lyzer, SIFT sorting intolerant from tolerant
+/, Responsible for depositing the variant in LOVD indicates that it affects function, but the curator of LOVD did not classify this variant as 
pathogenic
Variants PolyPhen-2 SIFT Mutation taster PROVEAN Align-GV/GD Functional analysis CLINVAR LOVD
(0–1) (0–1) (prob) (-13–4) (C0-C65)
c.313T>A Benign Tolerated Disease causing Neutral 250 C55 NA NA NA
(S105T) (0.035) (0.41) (− 58) (− 0.80)
c.387G>T Benign Tolerated Disease causing Neutral 250 C15 NA NA NA
(Q129H) (0.000) (0.36) (− 24) (0.05)
c.1676G>A Benign Tolerated Disease causing Neutral 250 C45 NA NA NA
(S559N) (0.000) (− 1) (− 46) (1.94)
c.1806C>A Benign Tolerated Disease causing Neutral 250 C15 NA NA NA
(F602L) (0.140) (0.2) (− 22) (0.07)




(A617T) (0.040) (0.19) (− 58) (− 0.72)
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of 178 bp, another one of approximately 300 bp was detected, 
and for sample GH80, besides the amplicon of 271 bp, an 
additional product of 100 bp was detected. Sequencing the 
products of samples GH12, GH68 (amplicon 300 bp) and 
GH80 (amplicon 100 bp) revealed only the universal primer 
M13 sequence. For sample GH68, sequencing of the 178 
amplicon showed the wild-type exons 3–4 sequence, without 
the germline variant c.387G>T, which is located in a canoni-
cal splice region, indicating that only the mRNA from the 
normal allele was recovered (Supplementary Figure 2). In 
addition, sequencing of the 271 bp amplicon from sample 
GH80 disclosed the wild-type sequence of exons 15–16.
Diet and lifestyle habits of EOGC patients
The diet/lifestyle habits of EOGC patients were compared to 
Brazilian population diet and lifestyle, according to public 
governmental databases. EOGC patients had a higher red 
(OR 2.6, 95% CI 1.4–4.9) and processed (OR 3.1, 95% CI 
1.6–6.0) meat intake as well as increased fruit consump-
tion compared to eating habits of the Brazilian population 
(OR 0.4, 95% IC 0.3–0.7). Moreover, a trend to increased 
consumption of food preserved in salt was observed (OR 
1.7, 95% CI 1.0–3.0; p = 0.051). However, there were no 
differences in tobacco and alcohol exposure in the Brazilian 
population and EOGC patients (Table 6).
Table 4  Analysis of CDH1 germline variants using in silico tools for splicing defect prediction
Values displayed on the left side and on the right side of the arrow refer, respectively, to wild-type and mutant alleles
Bold values indicate the significant values for splice site effect, according to splice prediction tools cited in materials and methods
UE unknown effect, like likely, NA not available, NR no result
= Unchanged between wild and mutant
Exon Variant HSF 3.0 MaxEnt NNSplice NetGene2 CLINVAR LOVD
0–100 (Δ%) − 20 to 20 (Δ%) 0–1 (Δ%) 0–1 (Δ%) (No. submission)
Intron 1 c.49-59G>T 89.94 → 79.07 3.46 → 5.91 = 0.43 → 0.44 NA NA
(− 12.09%) (+ 70.81%) (+ 2.3%)
Intron 2 c.163+57 = NR = 0.43 → 0.44 NA NA
(+ 2.3%)
Intron 2 c.163+59 = NR = 0.37 → 0.36 NA NA
(− 2.7%)
Exon 3 c.313T>A 89.8 → 85.88 5.61 → 2.66 = 0.28 → 0.25 NA NA
(S105T) (− 4.37%) (− 52.58%) (− 10.71%)
Exon 3 c.324A>G 89.8 → 92.92 5.61 → 6.86 = 0.79 → 0.82 Benign (2) NA
(R108R) (+ 3.49%) (+ 22.28%) (+ 3.79%) Likely benign (1)
Exon 3 c.345G>A 69.5 → 69.1 NR = 0.79 → 0.66 Benign (3) UE
(T115T) (− 0.58%) (− 16.45%)
Exon 3 c.387G>T 88.42 →59.47 8.87 → 0.28 0.98 → 0.53 = NA NA
(Q129H) (− 32.74%) (− 96.84%) (− 45.92%)
Intron 3 c.387+27C>T = 5.02 → 4.94 0.77 → 0.83 0.79 → 0.76 NA UE
(− 1.59%) (+ 7.79%) (− 3.79%)
Intron 3 c.388-44C>T = NR = 0.54 → 0.56 NA UE
(+ 3.7%)
Intron 4 c.532-18C>T = 10.59 → 10.98 = = Benign (2) UE
(+ 3.68%) Likely benign (1)
Intron 6 c.833-16C>G = 8.1 → 7.8 0.88 → 0.74 0.30 → 0.25 Benign (1) UE
(− 3.7%) (− 15.90%) (− 16.67%) Likely benign (1)
Exon 11 c.1676G>A 74.28 → 45.34 NR = 0.27 → 0.25 NA NA
(S559N) (− 38.96%) (− 7.40%)
Exon 12 c.1806C>A 79.72 → 77.14 NR = 0.25 → 0.19 NA NA
(F602L) (− 3.24%) (− 24.00%)
Intron 15 c.2439+10C>T 67.5 → 68.75 NR = = Benign (2) UE
(+ 1.85%) Likely benign (1)
Intron 15 c.2439+56T>G 66.32 → 70.62 − 2.35 → 6.14 0.99 →0.99 0.92 → 0.91 NA NA
(+ 6.48%) (+ 361.28%) 0% (− 1.09%)
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Discussion
Gastric cancer remains one of the leading causes of cancer 
mortality in developing countries; however, studies evalu-
ating the influence of hereditary factors on gastric cancer 
burden in these countries are scarce. In a cohort of Brazilian 
EOGC patients screened for CDH1 mutations, a total of 24 
germline variants were identified, including nine variants 
never previously described in the literature. Although no 
definitive pathogenic mutations have been found, four novel 
missense VUS were detected. The analysis of the socio-
environmental risk factors, such as diet and lifestyle habits, 
revealed that patients with EOGC reported a significantly 
higher consumption of processed meat and red meat. To our 
knowledge, the present study represents the largest series 
analyzing the incidence and spectrum of CDH1 germline 
mutations in consecutive and unrelated EOGC patients in 
Latin America.
HDGC is an autosomal dominant neoplastic syndrome 
described in 1998 [36, 37]. Male and female CDH1 muta-
tion carriers have a 70% (95% CI 59–80%) and 56% (95% 
CI 44–69%) cumulative lifetime risk of developing diffuse 
gastric cancer, respectively. In addition, the lifetime risk of 
lobular breast cancer for female carriers is 42% (95% CI 
23–68%) [38]. Over the past 2 decades, approximately 160 
CDH1 germline variants have been published; the major-
ity were described in probands with strong family history 
of cancer and from countries with a low-incidence rate of 
stomach cancer.
Our study population included predominantly patients 
diagnosed with diffuse gastric cancer under 40 years old 
and without family history of cancer. It is important to high-
light that probands were originally from all the regions of 
Brazil. Approximately 50% of the participants were born in 
Brazilian states outside the Southeast region, with 38.6% 
coming from Northeast. Therefore, despite the fact that the 
recruitment was carried out at a single academic center in 
São Paulo city, the study population was not limited to the 
inhabitants of this part of Brazil.
Unequivocal pathogenic germline CDH1 variants were 
not identified in 88 EOCG patients in Brazil. In a systematic 
review, that compiled published series usually from regions 
of low incidence of gastric cancer, only 2.3% of the cases 
diagnosed with gastric cancer under 35 years carried patho-
genic CDH1 variants [12]. In high-incidence areas, Corso 
et al. reported germline variants less frequently, of which 
68.8% were missense mutations [39]. Therefore, an absence 
or a low frequency of definitely pathogenic mutations in our 
study was already expected, mainly because it was held in 
a middle/high-incidence country for gastric cancer, where 
exposure to external risk factors might predominate and, 
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Hansford et al. have recently cataloged all CDH1 variants 
identified so far [38]. Among the 155 mutations described, 
126 were pathogenic and 29 were VUS. Among the 126 
pathogenic mutations, only 16% were missense. On the other 
hand, among the 29 VUS, 86% were missense. In our study, 
among the 24 variants identified, 33.3% (8/24) were clas-
sified as benign-polymorphisms (4 intronic and 4 synony-
mous), 20.8% (5/24) as benign (4 intronic and 1 synonyms), 
29.2% (7/24) as probably benign (5 intronic, 1 synonymous 
and 1 missense), and 16.7% (4/24) as VUS (4 missense). 
Despite the fact that 16.7% of mutations found in CDH1 
are novel and have low allele frequency, the ideal approach 
that can definitely assess the potential pathogenicity of these 
changes is still a matter of debate [7, 40–42].
Among the four VUS, c.387G>T presented a low allele 
frequency (allele 1/119896; http://exac.broad insti tute.org/
varia nt/16-68835 796-G-T) and the other 3 variants were 
not described in EXAC. Therefore, the classification of the 
pathogenicity of these variants might be possible only by 
studying the other families with the same variants and with 
family history suggestive of hereditary diffuse gastric cancer 
syndrome or performing functional tests. All carriers identi-
fied in our study were diagnosed with the early onset diffuse 
gastric adenocarcinoma. However, they did not report fam-
ily history of stomach and/or breast cancer. Thus, segrega-
tion studies were not a viable approach. In addition, these 
variants have never been previously published or reported in 
CLINVAR and/or LOVD. Computational algorithms were 
Fig. 1  Electrophoresis of amplicons in agarose gel. RNA was 
extracted from FFPE  tumor samples, and after RT-PCR, amplicons 
detected in agarose gel were cloned in bacteria and sequenced. NLC 
normal breast tissue (FFPE), NC negative control, MCF7 breast can-
cer cell line, GH gastric cancer FFPE samples, Primer pair 2 CDH1 
Exons 3–4, Primer pair 5 CDH1 Exons 15–16, Primer pair 4 CDH1 
Exons 10–12
Table 6  Odds ratio for dietary 
habits/lifestyle between 
EOGC patients and Brazilian 
population
CI confidence interval, IBGE Instituto Brasileiro de Geografia e Estatística, INPAD Instituto Nacional de 
Ciência e Tecnologia  para Políticas Públicas do Álcool e outras Drogas, OR odds ratio, SISVAN Sistema 
de Vigilância Alimentar e Nutricional
a Statistically significant
Factors Exposure OR 95% CI p Pop data source
Tobacco Ever (vs never) 1.5 1.0–2.3 0.080 IBGE, 2013 [29]
Alcohol Last 6 months (yes vs no) 1.7 0.9–3.0 0.094 INPAD, 2012 [31]
Fruits < 1x/week (vs ≥ 1x/week) 0.4 0.1–1.2 0.098 SISVAN, 2015 [30]
≤ 2x/week (vs ≥ 3x/week) 0.7 0.4– 1.1 0.146
≤ 5x/week (vs ≥ 6x/week) 0.4 0.3–0.7 < 0.001a
Leaves < 1x/week (vs ≥ 1x/week) 1.0 0.5–2.1 0.954 SISVAN, 2015 [30]
≤ 2x/week (vs ≥ 3x/week) 1.1 0.7–1.8 0.584
≤ 5x/week (vs ≥ 6x/week) 0.7 0.4–1.1 0.108
Salty food ≥ 1x/week (vs < 1x/week) 1.0 0.6–1.6 0.991 SISVAN, 2015 [30]
≥ 3x/week (vs ≤ 2x/week) 1.1 0.7–1.7 0.709
≥ 6x/week (vs ≤ 5x/week) 1.7 1.0–3.0 0.051
Processed meat ≥ 1x/week (vs < 1x/week) 1.0 0.6–1.5 0.827 SISVAN, 2015 [30]
≥ 3x/week (vs ≤ 2x/week) 1.7 1.0–2.8 0.034a
≥ 6x/week (vs ≤ 5x/week) 3.1 1.6–6.0 < 0.001a
Red meat ≥ 1x/week (vs < 1x/week) 2.1 0.4–10.9 0.389 IBGE, 2013 [29]
≥ 3x/week (vs ≤ 2x/week) 1.2 0.6–2.5 0.519
≥ 6x/week (vs ≤ 5x/week) 2.6 1.4–4.9 0.003a
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used to predict their pathogenicity, but the results were dis-
cordant among the prediction tools. These findings highlight 
that in silico predictions should be used with caution, as a 
complementary tool, and that important clinical decisions 
regarding the interpretation of variants cannot be made 
based on the in silico outcomes alone [42, 43]. Functional 
impact on splicing experiments, which may help in the char-
acterization of newly identified VUS, were performed.
The variant c.387G>T was further tested in mRNA from 
the patient’s tumor sample, because it is located on the exon/
intron boundary (last base exon 3). The splicing prediction 
tool indicated that the splicing site might be lost and a prob-
able novel splicing site might be located approximately 1460 
bases inside the intron (NNsplice: available at https ://omict 
ools.com/nnspl ice-tool, accessed November 2018). Our 
results, however, detected only the mRNA transcribed from 
the normal allele, because even the variant was not present 
in the amplicon. Based on these results, we still cannot infer 
the pathogenicity of the missense variant.
Our study was limited to explore the presence of germline 
variants only in the CDH1 gene and not in other gastric can-
cer predisposing genes. Although CDH1 is the most relevant 
gene, explaining about 40% of the cases, other genes may be 
involved in familial gastric cancer. Recently, new candidates 
have been identified including CTNNA1, BRCA1, BRCA2, 
STK11, PRSS1, PALB2, ATM, MSR1, SDHB, RAD51, and 
MAP3K6 [38, 44–46], but the clinical relevance of these 
findings still requires further validation.
Although the intestinal type of gastric cancer is associ-
ated with diet and lifestyle habits, the contribution of known 
modifiable risk factors to the incidence of diffuse-type gas-
tric cancer is still under investigation. In the report of Con-
tinuous Update Project, processed meat intake and alcohol 
consumption above moderate levels were associated with 
the increased risk of gastric cancer regardless of histology 
subtype. In addition, there is limited evidence if the con-
sumption of grilled fish, meat, and fruit affects the risk of 
developing gastric cancer [47]. In our study, in which the dif-
fuse type was predominant, patients with EOGC reported a 
significantly higher consumption of red and processed meat, 
as well as fruits, compared to the eating habits of the Bra-
zilian population. We did not find an association between 
alcohol intake and gastric cancer; however, alcohol exposure 
was measured in a very distinctive manner, evaluating any 
exposure in the last 6 months and not taking into account the 
amount of daily alcohol consumption (in grams per day) as 
usually reported [48]. Interestingly, although reports from 
Europe suggest that consuming little or no fruit increases the 
risk of gastric cancer [49], our findings showed the opposite 
effect and, as a consequence, require further investigation. 
The information about H. pylori infection is missing for the 
majority of our patients, but it is important to acknowledge 
that this well-established risk factor may also contribute to 
diffuse gastric cancer risk. Indeed, gastric cancer risk likely 
reflects a complex interaction among various diet and life-
style habits, and H. pylori infection may function as a con-
founder or potential effect modifier [50].
In conclusion, unequivocal pathogenic germline CDH1 
variants did not contribute significantly for EOGC predis-
position in our cohort and the assessment of the potential 
pathogenicity of missense variants still represents a major 
challenge. In addition, it was observed that the nutrition hab-
its of our patients are inadequate. For neoplasms like gastric 
cancer, in which the influence of external factors such as 
diet might increase the risk the disease, this information is 
relevant and warrants further investigation for the purpose 
of health promotion in the Brazilian population.
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